Açık Akademik Arşiv Sistemi

Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

Show simple item record

dc.contributor.authors Dal, MS; Ulu, BU; Uzay, A; Akay, OM; Besisik, S; Yenerel, MN; Çelik, S; Kaynar, L; Yücel, OK; Deveci, B; Sönmez, M; Mehtap, Ö; Beköz, HS; Sunu, C; Salim, O; Ulas, T; Karti, S; Altuntas, F; Ferhanoglu, B; Tuglular, TF
dc.date.accessioned 2024-02-23T11:45:09Z
dc.date.available 2024-02-23T11:45:09Z
dc.date.issued 2023
dc.identifier.issn 0939-5555
dc.identifier.uri http://dx.doi.org/10.1007/s00277-022-05052-x
dc.identifier.uri https://hdl.handle.net/20.500.12619/102152
dc.description Bu yayın 06.11.1981 tarihli ve 17506 sayılı Resmî Gazete’de yayımlanan 2547 sayılı Yükseköğretim Kanunu’nun 4/c, 12/c, 42/c ve 42/d maddelerine dayalı 12/12/2019 tarih, 543 sayılı ve 05 numaralı Üniversite Senato Kararı ile hazırlanan Sakarya Üniversitesi Açık Bilim ve Açık Akademik Arşiv Yönergesi gereğince açık akademik arşiv sistemine açık erişim olarak yüklenmiştir.
dc.description.abstract Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to April 2021 from 32 centers in Turkey. All patients received up to six cycles of Pola 1.8 mg/kg, rituximab 375 mg/m(2) on day 1, and bendamustine 90 mg/m(2) on days 1-2 of each cycle. Median age at Pola-BR initiation was 55 (19-84). The overall response rate was 47.9%, including 32.4% CR rate when a median of 3 cycles was applied. With a median follow-up of 5 months, the median OS was 5 months. Grade 3-4 neutropenia and thrombocytopenia were the most common hematological toxicities. The real-world data from our cohort showed the Pola-BR is an effective option with a manageable toxicity profile.
dc.language English
dc.language.iso eng
dc.publisher SPRINGER
dc.relation.isversionof 10.1007/s00277-022-05052-x
dc.subject Diffuse large B-cell lymphoma
dc.subject Polatuzumab vedotin
dc.subject Refractory
dc.subject Relapsed
dc.subject Rituximab
dc.subject Bendamustine
dc.title Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
dc.type Article
dc.identifier.volume 102
dc.identifier.startpage 133
dc.identifier.endpage 140
dc.relation.journal ANNALS OF HEMATOLOGY
dc.identifier.issue 1
dc.identifier.doi 10.1007/s00277-022-05052-x
dc.identifier.eissn 1432-0584
dc.contributor.author Dal, Mehmet Sinan
dc.contributor.author Ulu, Bahar Uncu
dc.contributor.author Uzay, Ant
dc.contributor.author Akay, Olga Meltem
dc.contributor.author Besisik, Sevgi
dc.contributor.author Yenerel, Mustafa Nuri
dc.contributor.author Celik, Serhat
dc.contributor.author Kaynar, Leylagul
dc.contributor.author Yucel, Orhan Kemal
dc.contributor.author Deveci, Burak
dc.contributor.author Sonmez, Mehmet
dc.contributor.author Mehtap, Ozgur
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rights.openaccessdesignations Bronze, Green Published


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record